



Evaluation of the efficacy of immune plasma treatment in COVID-19 infected intensive care unit patients

Emel Yıldız^{a,*} , Murat Emre Tokur^a , Bugra Özlem^a , Özlem Arık^b , Canan Balcı^a 

^a Department of Anesthesiology, Kütahya Health Sciences University Evliya, Çelebi Training and Research Hospital, Turkey

^b Department of Biostatistics, Kütahya Health Sciences University Evliya, Çelebi Training and Research Hospital, Turkey

ARTICLE INFO

Article history:

Received 20 November 2021

Received in revised form 15

December 2021

Accepted 06 January 2022

Keywords:

COVID-19

Immune plasma

Intensive care unit

Mortality

ABSTRACT

Introduction: Treatment approach in COVID-19 infection consists of antiviral, immunomodulatory, and supportive treatments. Convalescent plasma, immune plasma or hyperimmune plasma refers to the plasma that consisting of high titer polyclonal antibodies against the virus and are amidst the immunomodulatory treatments. Although it has been reported that immune plasma treatment of COVID-19 reduces hospital stay and mortality, the efficacy of immune plasma with COVID-19 infection is not clear yet. The present study aims to investigate the efficacy of immune plasma in patients who are followed up in the intensive care unit with the diagnosis of COVID-19.

Materials and methods: In this retrospective study, the patients who were hospitalized in the intensive care unit with the diagnosis of COVID-19 infection were divided into two groups: those who received IP treatment (Group 1; n=28) and those who did not (Group 2; n=25). The biochemical C -reactive protein, lactate-dehydrogenase, ferritin, D-dimer, total bilirubin, creatine levels, hematological parameters (Leukocyte, neutrophil, lymphocyte, platelet counts), clinical sepsis scores (SOFA, APACHE scores) and mortality rates of the patients were evaluated according to groups.

Results: There was no statistically significant difference between Group 1 and Group 2 in terms of the presence of mechanical ventilation support and tracheostomy, comorbidities, laboratory values, C -reactive protein, SOFA, APACHE scores. The mortality rate was 61% in Group 1 and 52% in Group 2.

Conclusions: Our findings revealed that immune plasma treatment was not effective in recovery and decreasing the mortality rates in the COVID-19 infected intensive care unit patients. Further studies are needed to investigate the efficacy of administering immunomodulatory therapies on the outcome before the hyper inflammatory process starts.

© 2022 The Authors. Published by Iberoamerican Journal of Medicine. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

* Corresponding author.

E-mail address: dremelyldz@gmail.com

ISSN: 2695-5075 / © 2022 The Authors. Published by Iberoamerican Journal of Medicine. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

<https://doi.org/10.53986/ibjm.2022.0009>

Evaluación de la eficacia del tratamiento con plasma inmune en pacientes de la unidad de cuidados intensivos infectados por COVID-19

INFO. ARTÍCULO

Historia del artículo:

Recibido 20 Noviembre 2021
Recibido en forma revisada 15
Diciembre 2021
Aceptado 06 Enero 2022

Palabras clave:

COVID-19
Plasma inmune
Unidad de Cuidados Intensivos
Mortalidad

RESUMEN

Introducción: El enfoque de tratamiento en la infección por COVID-19 consiste en tratamientos antivirales, inmunomoduladores y de apoyo. El plasma de convalecencia, el plasma inmune o el plasma hiperinmune se refieren al plasma que consiste en anticuerpos policlonales de alto título contra el virus y se encuentra en medio de los tratamientos inmunomoduladores. Aunque se ha informado que el tratamiento con plasma inmune de COVID-19 reduce la estancia hospitalaria y la mortalidad, la eficacia del plasma inmune con la infección por COVID-19 aún no está clara. El presente estudio tiene como objetivo investigar la eficacia del plasma inmune en pacientes que son seguidos en la unidad de cuidados intensivos con el diagnóstico de COVID-19.

Materiales y métodos: En este estudio retrospectivo, los pacientes que fueron hospitalizados en la unidad de cuidados intensivos con el diagnóstico de infección por COVID-19 se dividieron en dos grupos: los que recibieron tratamiento IP (Grupo 1; n = 28) y los que lo hicieron. no (Grupo 2; n = 25). La proteína C reactiva bioquímica, lactato-deshidrogenasa, ferritina, dímero D, bilirrubina total, niveles de creatina, parámetros hematológicos (recuentos de leucocitos, neutrófilos, linfocitos, plaquetas), puntuaciones de sepsis clínica (puntuaciones SOFA, APACHE) y tasas de mortalidad de los pacientes fueron evaluados según grupos.

Resultados: No hubo diferencia estadísticamente significativa entre el Grupo 1 y el Grupo 2 en cuanto a la presencia de soporte ventilatorio mecánico y traqueotomía, comorbilidades, valores de laboratorio, proteína C reactiva, SOFA, puntajes APACHE. La tasa de mortalidad fue del 61% en el grupo 1 y del 52% en el grupo 2.

Conclusiones: Nuestros hallazgos revelaron que el tratamiento con plasma inmune no fue efectivo en la recuperación y la disminución de las tasas de mortalidad en los pacientes de la unidad de cuidados intensivos infectados por COVID-19. Se necesitan más estudios para investigar la eficacia de la administración de terapias inmunomoduladoras sobre el resultado antes de que comience el proceso hiperinflamatorio.

© 2022 Los Autores. Publicado por Iberoamerican Journal of Medicine. Éste es un artículo en acceso abierto bajo licencia CC BY (<http://creativecommons.org/licenses/by/4.0/>).

HOW TO CITE THIS ARTICLE: Yildiz E, Tokur ME, Özlem B, Arik Ö, Baldi C. Evaluation of the efficacy of immune plasma treatment in COVID-19 infected intensive care unit patients. *Iberoam J Med.* 2022;4(1):37-44. doi: 10.53986/ibjm.2022.0009.

1. INTRODUCTION

The coronavirus disease 2019 (COVID-19), which started in Wuhan, China, spread worldwide. This novel coronavirus had been named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by the International Virus Taxonomy Committee [1]. On February 11, 2020, the disease was officially named COVID-19 by the World Health Organization (WHO) [2]. According to WHO data, approximately 275 million cases and 5 million deaths had been reported until 3 January 2021- 22 December 2021 [3]. Mortality in COVID-19 is higher than seasonal flu, which has a generally less than 0.1% mortality rate. Smoking, chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypertension (HT), cardiovascular diseases (CVD) and a history of malignant findings are also the risk factors that increase mortality in COVID-19 [2, 3].

To this date, no drugs have been approved to treat or prevent

COVID-19. All treatment is planned according to experience. In the treatment of COVID-19, antiviral treatments are used as well as immunosuppressive and immunomodulatory treatments [4]. Immune plasma (IP) IP is one of the immunomodulatory treatments used in the treatment of COVID-19, which is a passive antibody treatment and occurs against the virus in the blood of a person who has had COVID-19 infection, has been evaluated as a promising and potential treatment option since the beginning of the COVID-19 pandemic [5]. On March 24, 2020, the Food and Drug Administration (FDA) approved IP treatment for critical COVID-19 patients as long as their approval is obtained. IP has previously been shown to effectively treat H1N1, SARS, and MERS viruses [6]. According to the FDA, eligible IP recipients are COVID-19 positive patients with severe or life-threatening complications (Table 1). The life-threatening complications are considered to include pulmonary failure, septic shock, multiorgan failure, or dysfunction [7].

Table 1: Ministry of Health IP treatment updated guidelines [8, 9]

COVID-19 immune (convalescent) plasma supply and clinical use guidelines	April-June 2020	October 2020
Date of onset after symptom	7-14 days	Within seven days at the latest
Indications	Persistent fever (7 days) Lung infiltration of >50% within 24-48 hours, Respiratory frequency ≥ 30 /minute, PaO ₂ /FiO ₂ <300 mm Hg, 5 L/minute despite nasal oxygen support SpO ₂ <90%. 5 L/min Pao ₂ <70 mm Hg despite nasal oxygen support.	being over the age of 60, or Being between the ages of 18-60 and having serious comorbidities (cancer, COPD, cardiovascular disease, hypertension, diabetes mellitus) or Being between the ages of 18-60, using drugs that suppress the immune system/having a disease that suppresses the immune system; Absence of pneumonia signs.
Immune plasma administration in critically ill patients	Mechanical ventilation need, Minimum 2 point increase in SOFA score, Vasopressors need, Patients with an expected rapid clinical progression and poor prognostic parameters (severe lymphopenia; high CRP; high sedimentation, ferritin, LDH, or d-dimer). Recommended for use.	Recommended to be given before the need for intensive care develops. Its use is not recommended after the onset of symptoms with cytokine storm stands out (findings such as persistent fever despite treatment, persistently high or increasing CRP and ferritin values, cytopenias in the form of high D-dimer, lymphopenia, and thrombocytopenia, impairment in liver function tests, hypofibrinogenemia or increased triglyceride values).

PaO₂: Partial pressure of oxygen in arterial blood; FiO₂: Fraction of inspired oxygen; SpO₂: Oxygen saturation; SOFA: Sequential Organ Failure Assessment; CRP: C-reactive protein; LDH: Lactate-dehydrogenase COPD: Chronic obstructive pulmonary disease.

Studies on the efficacy of IP in previous pandemics in the literature have found that it reduces the rate of hospitalization and mortality. Although IP can be therapeutic in critically ill COVID-19 patients, clinical benefit is not yet known despite its usage.

Our study aims to determine the effectiveness of IP in patients diagnosed with COVID-19 that we followed in the ICU.

2. MATERIALS AND METHODS

To conduct the study, ethics committee approval was obtained from Kütahya Health Sciences University, Non-Interventional Ethics Committee with the decree number 2021/02-23, dated 09.02.2021. In this retrospective study, the patients who were hospitalized in the 8-bed pandemic ICU with the diagnosis of COVID-19 infection between April 2020 and July 2020, were included. The patients were divided into two groups, those who received IP treatment (Group 1; n=28) and those who did not (Group 2; n=25). The data of patients were retrospectively scanned from the patient files and the hospital automation system. The age, gender, and comorbid diseases of the patients were examined. It was recorded whether the patient needed

mechanical ventilation, the number of days the patient received mechanical ventilation support, and whether the tracheostomy was performed. The hospitalization duration in the ICU, the Acute Physiology and Chronic Health Evaluation (APACHE) scoring, and the Sequential Organ Failure Assessment (SOFA) scoring, and mortality status of the patients were determined. The biochemical C-reactive protein (CRP), lactate-dehydrogenase (LDH), ferritin, D-dimer, total bilirubin, creatine levels, hematological parameters (leukocyte, neutrophil, lymphocyte, platelet counts), clinical sepsis scores, (SOFA, APACHE scores), and mortality rates of the patients were evaluated according to groups. Voluntary standard donor selection criteria from which immune plasma to be used in the treatment of COVID-19 will be procured were made in accordance with the instructions of the "Ulusal Kan ve Kan Bileşenleri Hazırlama, Kullanım ve Kalite Güvencesi Rehberi" and "European Medicines and Health Services Quality Directorate (EDQM)" [10].

Immune plasma taken from the donor by apheresis method; It can be stored for 3 years by freezing below -25 degrees. In patients for whom immune plasma therapy was planned, serum IgA levels were measured. It was found to be normal. Immune plasma to be given to the patients in Group 1 was melted from the frozen state to the appropriate temperature and given through a large intravenous intravenous line

Table 2: Demographic characteristics (age-gender) mechanical ventilation support, presence of tracheostomy, comorbidity, the first day of immune plasma administration, mortality

Variables	Group 1 (n=28)	Group 2 (n=25)	p-value
Age (min-max range)	67.35±11.56 (41-94)	70.64±13.61 (39-99)	0.347
Gender (n (%))			
Male	17 (60.70%)	10 (40%)	0.132
Female	11 (39.30%)	15 (60%)	
Mechanical ventilation (n (%))			
Yes	16 (57.10%)	13 (52%)	0.707
No	12 (42.90%)	12 (48%)	
Tracheostomy (n (%))			
Yes	3 (10.70%)	0 (0%)	0.092
No	25 (89.30%)	25 (100%)	
Comorbid disease	Alzheimer, DM, Hypothyroidism, Silicosis, CAH, RA, SVO, COPD	Alzheimer, CAD, CHF, DM, HT, COPD, CRF, RA, SVO, Parkinson	0.478
Immune plasma administration day (min-max range)	7.46±4.54 (1-20)	-	
Deceased (n (%))	17 (60.70%)	13 (52%)	0.523
Inpatient Clinic (n (%))	11 (39.30%)	12 (48%)	

Age and immune plasma values are expressed as mean ± standard deviation. P value statistically significant: $p < 0.05$.

CAD: Coronary Artery Disease; CHF: Congestive Heart Failure; DM: Diabetes Mellitus; HT: Hypertension; COPD: Chronic obstructive pulmonary disease; CRF: Chronic Renal Failure; RA: Rheumatoid Arthritis; CV: Cardiovascular event.

within 30 minutes. IP was administered in group 1 on the 7th day of hospitalization (min: 1, max: 20) in intensive care. It was found that two doses of IP were administered to the patients is 200 milliliters in group 1 with an interval of 48 hours. The results were checked after the second dose of IP. The minimum recommended dose for a patient is 200 millilitres that had a neutralized antibody titer of at least 1:640 of COVID-19 immuneplasma unit. 1 unit per day, 1-2 doses at 48 hours intervals, maximum 3 doses (600 millilitres) if necessary is in the form [9]. The patients in group 2 were those who were not given immune plasma. The COVID-19 diagnosis was made according to WHO COVID-19 diagnostic criteria [2]. A COVID-19 polymerase chain reaction (PCR) test positivity from an upper respiratory tract swab sample, being 18 years of age and older, having symptoms for COVID-19 (fever, cough, shortness of breath patients) as conditions chosen and included in the study. The patients who do not meet these criteria are excluded from the study.

2.1. STATISTICAL ANALYSIS

In order to obtain the results in the tables, which contains the demographic characteristics, laboratory values, clinical and treatment characteristics of the study, a two-sample t-test was used for variables that provided parametric test assumptions such as the normal distribution assumption, and Mann-Whitney U test for non-parametric and variables which the assumption was not provided. Also, through chi-square test analysis (Pearson chi-square, Phi, Cramer's V, Contingency Coefficient) conditions such as relationship and difference between categorical variables were examined

(* $p < 0.05$). While the mean and standard deviation values of the variables were presented in the data, which the two-sample t-test was performed, in the data where the Mann Whitney-U test was used, the median (median) and first quartile (25%) values of the variables were presented. In the study, variables, which were considered to valid for differences between groups, such as age, CRP, SOFA, Apache, Apache rate, and hospitalization duration in the intensive care unit (days) were evaluated with parametric tests and other variables with non-parametric tests. While evaluating the study's findings, IBM SPSS (Statistical Package for Social Sciences) Statistics 20 program was used for statistical analysis.

3. RESULTS

Patients followed in the intensive care unit with the diagnosis of COVID-19 were included in the study. A power analysis of the study, which included 53 patients, was performed. Fifty-three patients who were followed up in the ICU with the diagnosis of COVID-19 were included in the study. Using the significance test of the difference between two independent means, the power of the test was calculated as 0.81 when the sample numbers were studied with 28 and 25 in the groups with an effect size of 0.8 and a significance level of 0.05 (95% confidence level). Supportive treatment and oxygen support were administered after all patients in both groups, which were admitted to the ICU. It was found that hydroxychloroquine and azithromycin were given as antiviral treatment. The mean age of the patients in both

groups was over 65 years. 60% and 40% of the patients were male in group 1 and group 2 respectively. There was no statistically significant difference between group 1 and group 2 in terms of mean age values ($p=0.347$) and gender distribution of the individuals ($p=0.132$).

terms of mean CRP, SOFA, and Apache scores. There was a statistically significant difference between the two groups only in terms of the mean duration of hospitalization in the intensive care unit. The mean value of hospitalization duration in the intensive care unit was 13.9 ± 6.8 days in

Table 3: CRP, SOFA, APACHE, duration of hospitalization in the Intensive Care Unit

Variables	Group 1 (n=28)	Group 2 (n=25)	p-value
CRP (mg/L) (min-max range)	145.10±99.52 (2.22-342)	126.38±95.84 (8.83-354)	0.490
SOFA	7.14±4.60 (1-13)	6.68±3.99 (1-13)	0.699
APACHE	17.28±7.17 (4-29)	21.48±10.36 (4-44)	0.090
APACHE (%)	31.60±20.04 (5-67.1)	41.28±28.18 (5-94.8)	0.152
Duration of hospitalization in intensive care (days)	13.93±6.85 (2-31)	5.40±4.65 (1-17)	0.000*

Values are expressed as mean ± standard deviation. P value statistically significant: * $p<0.05$.

CRP: C-reactive protein; SOFA: Sequential Organ Failure Assessment; APACHE: Acute Physiology and Chronic Health Evaluation.

While 57% of patients in group 1 had mechanical ventilation, 43% did not have mechanical ventilation. While 52% of the patients in group 2 had mechanical ventilation; 48% did not have mechanical ventilation. There was no statistically significant difference between the groups in terms of the mechanical ventilation support ($p=0.707$). While 89% of the patients in group 1 did not have a tracheostomy; 11% had tracheostomy. Not all patients in group 2 had tracheostomy. No statistically significant difference was found between the groups in terms of the presence of tracheostomy ($p=0.092$). When the patients' comorbid diseases were examined, there was no statistically significant difference between the two groups. Approximately 39% of the patients in group 1 and 40% of the patients in group 2 were transferred to the pandemic inpatient clinic. While 61% of the patients in group 1 died, the death rate was 52% in the group 2 (Table 2). When the data in both groups were examined, there was no statistically significant difference between the two groups in

group 1, while it was 5.4 ± 4.6 in group 2 (Table 3).

No statistically significant difference was found in the monitored laboratory values of the patients in both groups (Table 4). There was no statistically significant change in the laboratory results of the patients in group 1.

4. DISCUSSION

In terminology, convalescent plasma and hyperimmune plasma terms are used, and they refer to plasma consisting of high titer polyclonal antibodies against the virus. The antibodies found in IP may kill the virus in four ways. The first is viral neutralization by coating the virus. The second is the virolysis by activating the complement directly. The third is to facilitate the virus's uptake by immune cells, and the fourth is to promote the death of virus-infected cells [11]. Special laboratories and tests should control the antibody level in IP. However, this may not be possible for every

Table 4: Laboratory values of patients

Variables	Group 1 (n=28)	Group 2 (n=25)	p-value
Mechanical ventilation (days)	8±0 (0-30)	1.5±0 (0-12)	0.062
LDH (u/L)	412.50±321.50 (186-4557)	342±239.50 (121-949)	0.092
WBC ($10^3/uL$)	11320±7932.50 (4750-20720)	10510±8410 (4350-35130)	0.695
Platelet ($10^3/uL$)	211500±147500 (70000-557000)	237000±164500 (21000-599000)	0.762
Lymphocyte/Neutrophil (%)	7.40±3.95 (1.90-69)	6±4.75 (2.20-53.60)	0.964
Lymphocyte ($10^3/uL$)	765±475 (190-2430)	800±445 (290-3210)	0.618
Bilirubin (mg/dL)	0.71±0.53 (0.24-4.24)	0.65±0.43 (0.30-3.67)	0.845
Creatine (mg/dL)	0.93±0.70 (0.52-5.82)	1.10±0.83 (0.56-6.08)	0.173
D-Dimer (ng/mL)	1565.50±844.25 (0-7451)	1659±909 (0-7659)	0.695
Ferritin (ug/L)	350.50±132.25 (0-1411)	172±52.50 (0-1334)	0.236

Values are expressed as median ± Q_1 (%25) as well as minimum and maximum range. P value statistically significant: * $p<0.05$.

LDH: Lactate-dehydrogenase; WBC: White blood count.

medical center. IP treatment started quickly in a pandemic like COVID-19. It was impossible to know the antibody titer in IP, which administered to patients at the beginning of the pandemic [12]. We administered IP treatment to patients diagnosed with COVID-19, which hospitalized in intensive care, in line with the Ministry of Health guidelines (8-9). However, the minimum recommended dose for a patient is 200 millilitres that had a neutralized antibody titer of at least 1:640 of COVID-19 immune plasma unit. Approximately 25.9% of patients diagnosed with COVID-19 are hospitalized in the ICU [13]. There is currently no vaccine or approved antiviral regimen for the treatment of critically ill patients. The treatments of patients diagnosed with COVID-19 in the ICU are treated with mainly supportive treatments such as infection control, hemodynamic stabilization, acute kidney injury and renal replacement therapy, pharmacologic interventions, extracorporeal membrane oxygenation, mechanical ventilation, and fluid management [14]. With this study, we aimed to determine the effectiveness of IP treatment in patients' diagnosed with COVID-19 in ICU. In our study, no statistically significant difference was found between the two groups in terms of mortality. While the patients' mortality rate in group 1 was 60.7% and 52% in group 2. IP was also used in the West African Ebola epidemic in 2013. Fifty three were included and groups with and without IP were compared. Shorter symptom duration was observed in the IP group. While the mortality risk was found to be 31% in the group with IP, and 38% in the group which not given [15]. The studies conducted with IP in the literature stated that early IP administration significantly reduced mortality [16-19]. Several studies also concluded that IP treatment does not affect mortality. In a study, by Ling et al. administered supportive treatment as well as IP to 52 patients diagnosed with severe COVID-19 and only supportive treatment to 51 patients. 28-day improvement was seen with 51.9% in the IP group and 43% in the supportive treatment group. No significant difference was observed in mortality rates between the two groups [20]. Zhen et al. compared the mortality of 6 patients which administered IP and 15 patients who were not which critically ill COVID-19 patient. As a result, they stated that IP could not reduce mortality in critically ill COVID-19 patients, and treatment should be started earlier [21]. In a meta-analysis conducted by Psaltopoulou et al. summarizing the available evidence on IP with COVID-19, which registered trials and guidelines from the authorities, they concluded that IP treatment should be administered in severe cases and as early as possible to maximize efficacy [22]. No significant difference was found between the two groups

in terms of WBC, lymphocyte, thrombocyte, lymphocyte, and neutrophil percentage. In the literature, it is stated that the regression in the infection parameters of the patients, especially lymphopenia, is an essential parameter for follow-up. Duan et al. determined that after IP administration to 10 patients diagnosed with COVID-19 in April 2020, oxygen saturation and lymphocyte values increased. They stated that IP could be used as promising rescue therapy for severe COVID-19 patients [23]. In the study, which conducted by Shen et al. published that the symptoms and laboratory values of five critical COVID-19 patients resistant to steroid and antiviral treatment after IP administration. It was reported that symptoms of five patients regressed three days after treatment, respiratory functions improved, lymphocyte count increased, and chest radiography findings improved after seven days [24]. Erku et al. did not find a significant difference in leukocyte, neutrophil, lymphocyte, thrombocyte, CRP, ferritin, LDH, ALT, AST, SpO₂, and total bilirubin values, which measured one week after the IP treatment given to 26 COVID-19 patients who were followed up in the intensive care unit. They stated that it could effectively treat patients in the early period without the need for mechanical ventilator support [25].

In a multi-center study conducted in Kuwait, Alsharidah et al. compared 135 patients who were given IP and 233 moderate and severe COVID-19 patients who did not. They found that the 30-day mortality was significantly lower in the group given IP and IP was significant in clinical improvement. They found that the number of lymphocytes increased, and CRP levels decreased in patients with administered IP [26]. In a study comparing 40 patients with and without IP, Omrani et al. found that the decrease in CRP, WBC, creatine, ferritin, and ALT values and the increase in thrombocyte and lymphocyte count were not different in both groups, and they concluded that the recovery of the patients was not directly related to IP [27].

Although IP has historically proven useful in treating some viral diseases, its use in the treatment of COVID-19 is still controversial. Although IP administration seems to be safe in studies conducted to date, transfusion-related acute lung injury is among the potential risks [28]. Another issue is the proper timing of the IP treatment. IP should be administered as early as possible to maximize efficacy and should be used in critically ill cases. However, the IP efficacy in COVID-19 infection is not yet clear. IP can be therapeutic in critically ill COVID-19 patients. Joyner et al. have revealed that IP, which given to 5000 patients diagnosed with COVID-19, is safe [29]. In our study, no severe side effects were observed.

In a pandemic, IP can be an easily accessible source of antiviral antibodies. Fresh frozen plasma (FFP) is a treatment used in many clinical indications with a well-known safety profile. In our country, in the guideline published in April 2020, it is recommended to use IP between 7-14 days, preferably after the onset of symptoms in COVID-19 patients [8]. In the guideline updated in October 2020, it is recommended to be used within seven days at the latest after the onset of symptoms [9].

The indications for IP administration were narrowed, and it was recommended to be given before intensive care. They stated that IP, which is given in critical condition and when cytokine storm develops, might harm the patient since the antibodies have already been developed (Table 1). In our patients, IP was applied approximately seven days after the ICU hospitalization. According to the recently updated guideline, it seems that it was administered later than the recommended time for the treatment of COVID-19. This may be why it was not statistically significant in terms of mortality and intensive care stay in both groups.

5. CONCLUSIONS

IP was used in the early stages of the pandemic in critical intensive care patients in the COVID-19 pandemic. As time passed, publications were stating that the earlier initiation of IP in the treatment of COVID-19 would be more effective. IP treatment was started before the patients came to the intensive care unit. As a result, administering convalescent plasma at an early stage of sickness should potentially be more effective.

Our findings revealed that immune plasma treatment was not effective in recovery and decreasing the mortality rates in the COVID-19 infected intensive care unit patients. Further studies are needed to investigate the efficacy of administering immunomodulatory therapies on the outcome before the hyperinflammatory process starts.

6. CONFLICT OF INTERESTS

The authors have no conflict of interest to declare. The authors declared that this study has received no financial support.

7. REFERENCES

1. Alkan Çeviker S, Dindar Demiray EK. [Other Respiratory Viruses for Differential Diagnosis of SARS-CoV-2 (COVID 19) Infection]. *J Biotechnol and Strategic Health Res.* 2020;1(Özel Sayı):45-9. doi: 10.34084/bshr.714383.
2. Kaur KK, Allahbadia G, Singh M. A comprehensive review on epidemiology, aetiopathogenesis, diagnosis and treatment of the novel coronavirus syndrome -- COVID-19. *Iberoam J Med.* 2020;2(2):110-23. doi: 10.5281/zenodo.3757110.
3. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy.* 2021;76(2):428-55. doi: 10.1111/all.14657.
4. Pascarella G, Strumia A, Piliago C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. *J Intern Med.* 2020;288(2):192-206. doi: 10.1111/joim.13091.
5. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest.* 2020;130(6):2757-65. doi: 10.1172/JCI138745.
6. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect Dis.* 2020;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9.
7. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. *BMJ.* 2020;368:m1256. doi: 10.1136/bmj.m1256.
8. Kurulu Çalışması BD. COVID-19 Pandemisinde Sağlık Kurumlarında Çalışma Rehberi ve Enfeksiyon Kontrol Önlemleri. 2021. Available from: <https://covid19.saglik.gov.tr/Eklenti/40282/0/covid19-saglikkurumlarindacalismarehberiveenfeksiyonkontrolonlemleripdf.pdf> (accessed May 2021).
9. T.C. SAĞLIK BAKANLIĞI SAĞLIK HİZMETLERİ GENEL MÜDÜRLÜĞÜ Kan ve Kan Ürünleri Dairesi Başkanlığı . COVID-19 İMMÜN (KONVALESAN) PLAZMA TEDARİK VE KLİNİK KULLANIM REHBERİ. Available from: <https://shgmkanhizmetleridb.saglik.gov.tr/Eklenti/39167/0/covid-19-immun-plazma-rehberi-v5.pdf>. (accessed May 2021).
10. Türkiye'de Kan Tedarik Sisteminin Güçlendirilmesi Teknik Destek Projesi. Ulusal kan ve kan bileşenleri hazırlama, kullanım ve kalite güvencesi rehberi. 2016. Available from: <https://shgmkanhizmetleridb.saglik.gov.tr/Eklenti/36313/0/kan-ve-kan-bilesen-rehb-tr-9-mayis-2016-revpdf.pdf> (accessed May 2021).
11. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. *J Med Virol.* 2020;92(9):1475-83. doi: 10.1002/jmv.25961.
12. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med.* 2020;26(8):1200-4. doi: 10.1038/s41591-020-0965-6.
13. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents.* 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924.
14. Castro MG, Sardonio MJ, Castillo Landaburo AA, Cuevas G, Cogliano F, Galluccio F. Predicting of poor outcomes in COVID-19 patients: Experience from an Argentinean hospital. *Iberoam J Med.* 2021;3(4):316-25. doi: 10.53986/ibjm.2021.0050.
15. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. *N Engl J Med.* 2016;374(1):33-42. doi: 10.1056/NEJMoa1511812.
16. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J Infect Dis.* 2015;211(1):80-90. doi: 10.1093/infdis/jiu396.
17. Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus

infection: a study protocol. *Springerplus*. 2015;4:709. doi: 10.1186/s40064-015-1490-9.

18. Hegerova L, Gooley TA, Sweerus KA, Maree C, Bailey N, Bailey M, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. *Blood*. 2020;136(6):759-62. doi: 10.1182/blood.2020006964.

19. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clin Microbiol Infect*. 2004;10(7):676-8. doi: 10.1111/j.1469-0691.2004.00956.x.

20. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA*. 2020;324(5):460-70. doi: 10.1001/jama.2020.10044.

21. Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. *J Infect Dis*. 2020;222(1):38-43. doi: 10.1093/infdis/jiaa228.

22. Psaltopoulou T, Serghianis TN, Pappa V, Politou M, Terpos E, Tsioufas S, et al. The Emerging Role of Convalescent Plasma in the Treatment of COVID-19. *Hemasphere*. 2020;4(3):e409. doi: 10.1097/HS9.0000000000000409.

23. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A*. 2020;117(17):9490-6. doi: 10.1073/pnas.2004168117.

24. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA*. 2020;323(16):1582-9. doi: 10.1001/jama.2020.4783.

25. Erkurt MA, Sarici A, Berber İ, Kuku İ, Kaya E, Özgül M. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from

eastern Anatolia. *Transfus Apher Sci*. 2020;59(5):102867. doi: 10.1016/j.transci.2020.102867.

26. Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, Alshammari FR, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. *Int J Infect Dis*. 2021;103:439-46. doi: 10.1016/j.ijid.2020.11.198.

27. Omrani AS, Zaout A, Baiou A, Daghfal J, Elkum N, Alattar RA, et al. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report. *J Med Virol*. 2021;93(3):1678-86. doi: 10.1002/jmv.26537.

28. Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. *Trials*. 2020;21(1):499. doi: 10.1186/s13063-020-04422-y.

29. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. *J Clin Invest*. 2020;130(9):4791-7. doi: 10.1172/JCI140200.